Klaus Engelke, Thomas Fuerst, Bernard Dardzinski, John Kornak, Shabana Ather, Harry K Genant, Anne de Papp
Odanacatib, a selective cathepsin K inhibitor, increases areal bone mineral density (aBMD) at the spine and hip of postmenopausal women. To gain additional insight into the effects on trabecular and cortical bone, we analyzed quantitative computed tomography (QCT) data of postmenopausal women treated with odanacatib using Medical Image Analysis Framework (MIAF; Institute of Medical Physics, University of Erlangen, Erlangen, Germany). This international, randomized, double-blind, placebo-controlled, 2-year, phase 3 trial enrolled 214 postmenopausal women (mean age 64 years) with low aBMD...
January 2015: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research